Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Ilaris
Descriptions
Canakinumab injection is used to treat cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). CAPS is a rare, inherited disease of the immune system.
Canakinumab injection is also used to treat tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF).
Canakinumab injection is also used to treat active Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA).
CAPS, TRAPS, HIDS/MKD, and FMF are autoinflammatory periodic fever syndromes and Still's disease is an autoinflammatory disease. Autoinflammatory conditions occur when the body produces too much of a chemical called interleukin-1 beta. This chemical causes inflammation (swelling) and patients may have a fever, headache, skin rash, joint or muscle pain, or unusual tiredness or weakness. Canakinumab is an interleukin-1 beta blocker. It helps prevent inflammation by keeping the interleukin-1 beta from working properly.
This medicine is to be given only by or under the direct supervision of a doctor.
This product is available in the following dosage forms:
Portions of this document last updated: March 01, 2021
Copyright © 2021 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.